BMS-986235 (C008B-270150)

BMS-986235 (LAR-1219) is a selective, orally active formyl peptide receptor 2 (FPR2) agonist, with EC 50 s of 0.41 nM and 3.4 nM for hFPR2 and mFPR2, respectively. BMS-986235 has potential for the prevention of heart failureIn VitroBMS-986235 (LAR-1219) inhibits neutrophil chemotaxis and stimulats macrophage phagocytosis, key end points to promote resolution of inflammation. In VivoBMS-986235 (LAR-1219) (0.3 mg/kg; p.o.; daily for 24 days) can attenuate left ventricle and global cardiac remodeling after left anterior descending (LAD) in mice . BMS-986235 (1 mg/kg; p.o.) treatment shows the C max , T 1/2 , AUC 0-inf , and bioavailability (BA) values of 160 nmol/L, 0.68 hours,120 nmol/L•h, and 24%, respectively . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Male C57BL/6 mice Dosage: 0.3 mg/kg Administration: P.o.; daily for 24 days Result: Left ventricle (LV) chamber remodeling is attenuated after myocardial infarction (MI). Reduced infarct length by 39% relative to vehicle. Animal Model: Male mice (BALB/cCrSlc) Dosage: 1 mg/kg Administration: P.o. (Pharmacokinetic Analysis) Result: The C max , T 1/2 , AUC 0-inf , and bioavailability (BA) values were 160 nmol/L, 0.68 hours, 120 nmol/L•h, and 24%, respectively.IC50& Target:EC50: 0.41 nM (human FPR2), 3.4 nM (mouse FPR2), 2800 nM (human FPR1)

Specifications & Purity: BMS-986235 (LAR-1219) is a selective, orally active formyl peptide receptor 2 (FPR2) agonist, with EC 50 s of 0.41 nM and 3.4 nM for hFPR2 and mFPR2, respectively. BMS-986235 has potential for the prevention of heart failureIn VitroBMS-986235 (LAR-1219) inhibits neutrophil chemotaxis and stimulats macrophage phagocytosis, key end points to promote resolution of inflammation. In VivoBMS-986235 (LAR-1219) (0.3 mg/kg; p.o.; daily for 24 days) can attenuate left ventricle and global cardiac remodeling after left anterior descending (LAD) in mice . BMS-986235 (1 mg/kg; p.o.) treatment shows the C max , T 1/2 , AUC 0-inf , and bioavailability (BA) values of 160 nmol/L, 0.68 hours,120 nmol/L•h, and 24%, respectively . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Male C57BL/6 mice Dosage: 0.3 mg/kg Administration: P.o.; daily for 24 days Result: Left ventricle (LV) chamber remodeling is attenuated after myocardial infarction (MI). Reduced infarct length by 39% relative to vehicle. Animal Model: Male mice (BALB/cCrSlc) Dosage: 1 mg/kg Administration: P.o. (Pharmacokinetic Analysis) Result: The C max , T 1/2 , AUC 0-inf , and bioavailability (BA) values were 160 nmol/L, 0.68 hours, 120 nmol/L•h, and 24%, respectively.IC50& Target:EC50: 0.41 nM (human FPR2), 3.4 nM (mouse FPR2), 2800 nM (human FPR1)

Grade: Moligand™

Molecular Formula: C18H17F2N3O3

Molecular Weight: 361.3

PubChem CID: 122583088

Isomeric SMILES: COC1=CC(=C(C(=C1)F)[C@@H]2CNC(=O)[C@H]2NC(=O)NC3=CC=CC=C3)F

Storage Temperature: Store at -20°C

Shipped in: Ice chest + Ice pads

UPC:

51442714

Weight:

1.09 Ounces

HazmatClass:

Yes

Quantity:

1

Unit of Measurement:

EA

WeightUOM:

LB

MPN:

B650857-25mg

Country of Origin:

China

CAS:

2253947-47-4

Product Size:

25mg

Harmonized Tariff Code:

2931.90.90